In today’s recent session, 1.24 million shares of the Grace Therapeutics Inc (NASDAQ:GRCE) have been traded, and its beta is 1.19. Most recently the company’s share price was $3.31, and it changed around $0.07 or 2.01% from the last close, which brings the market valuation of the company to $33.51M. GRCE at last check was trading at a discount to its 52-week high of $4.97, offering almost -50.15% off that amount. The share price’s 52-week low was $2.13, which indicates that the recent value has risen by an impressive 35.65% since then. We note from Grace Therapeutics Inc’s average daily trading volume that its 10-day average is 53390.0 shares, with the 3-month average coming to 65.85K.
Grace Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended GRCE as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Grace Therapeutics Inc is expected to report earnings per share of -0.45 for the current quarter.
Grace Therapeutics Inc (NASDAQ:GRCE) trade information
Instantly GRCE has been showing a green trend so far today with a performance of 2.01% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 3.55 on recent trading dayincreased the stock’s daily price by 6.76%. The company’s shares are currently down -11.63% year-to-date, but still up 2.64% over the last five days. On the other hand, Grace Therapeutics Inc (NASDAQ:GRCE) is -19.39% down in the 30-day period. We can see from the shorts that 0.13 million shares have been sold at a short interest cover period of 3.25 day(s).
Grace Therapeutics Inc (GRCE) estimates and forecasts
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 47.80%. Grace Therapeutics Inc earnings are expected to increase by 12.96% in 2025, but the outlook is positive 29.16% per year for the next five years.
